TAS-102 is a preconstituted drug combination comprising an oral fluoropyrimidine (trifluridine, TFT) and a potent inhibitor of thymidine phosphorylase (tipiracil hydrochloride, TPI). TFT/TPI has recently received Food and Drug Administration (FDA) approval also for the treatment of gastric cancer after at least two lines of chemotherapy. The approval was based on a large phase 3 trial (TAGS), in which TAS-102 showed a 31 % decrease in the risk of death compared with placebo. Here, we review the pharmacological properties, clinical development and potential future directions of TAS-102 in gastric cancer.

中文翻译：

---

TAS-102在胃癌中的应用：一种新型生物化学调节的氟尿嘧啶药物组合的开发和前景。

TAS-102是一种预制的药物组合，包含口服氟嘧啶（三氟吡啶，TFT）和有效的胸苷磷酸化酶抑制剂（盐酸替吡西酯，TPI）。TFT / TPI最近也获得了美国食品药品监督管理局（FDA）的批准，至少经过两轮化疗后，它还可以用于治疗胃癌。该批准基于一项大型的3期试验（TAGS），其中TAS-102与安慰剂相比，死亡风险降低了31％。在这里，我们审查TAS-102在胃癌中的药理特性，临床发展和潜在的未来方向。